Switching to camizestrant, a next-generation oral SERD, significantly prolongs progression-free survival and maintains ...

Aromatase inhibitors act through pure oestrogen deprivation to achieve an endocrine response in oestrogen receptor (ER)-positive breast cancer. Both experimental and clinical data now confirm that ...

Switching to a new drug combination — camizestrant plus a CDK4/6 inhibitor — sooner may have positive results for advanced breast cancer.

AstraZeneca has produced some fresh data to back up its blockbuster ambitions for camizestrant, tying the oral SERD to a 56% ...

Wyost and Jubbonti are interchangeable with Xgeva/Prolia and are approved for all of the same indications in bone cancer and osteoporosis.

Ipatasertib combined with fulvestrant significantly extends progression-free survival in ER-positive, HER2-negative ...

Data presented at ASCO show that swapping in the oral drug camizestrant for an older therapy helped sustain the benefit of initial treatment, potentially opening a novel step in patient care.

Positive results from the SERENA-6 Phase III trial have shown that AstraZeneca’s camizestrant alongside a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) led to a ...

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard treatments cut the risk ...

According to AZ, SERENA-6 is also the first pivotal trial to show the value of measuring circulating tumour DNA (ctDNA) to ...

AstraZeneca Plc (NASDAQ:AZN) on Monday released results from three Phase 3 clinical trials at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting: DESTINY-Breast09, MATTERHORN, and ...